Ischemic Stroke
Conditions
Brief summary
This study is to evaluated the safety and efficacy of BMSCs transplantation in the treatment of ischemic stroke, so as to provide a basis for future clinical application of BMSCs transplantation in the treatment of ischemic stroke.
Detailed description
1. Routine treatment: 1.1. If arterial plaque is found, use lipid-lowering therapy (routine dose of atorvastatin or rosuvastatin). If no plaque is found, use atorvastatin or rosuvastatin based on the maintenance of normal blood lipid; 1.2. If venous thrombosis or arterial plaques are found in the lower limbs, use dabigatran to prevent platelet aggregation; if no vascular problems are found in the lower limbs, use aspirin or clopidogrel to prevent platelet aggregation; 1.3. During the treatment, cerebrovascular stenosis (non responsible vessels) can be treated intravascularly; 1.4. The use of neurotrophic drugs is prohibited during the study; 1.5. Elevated homocysteine was treated with mecobalamin and folic acid; 1.6. Hypertension, diabetes and other basic diseases receive routine treatment, and the combined medication is recorded in the case report form. 2. Grouping: 2.1. BMSCs group: BMSCs were transplanted on the basis of routine treatment: the transplanted cells were injected intravenously and transplanted in two times, with a dose of 1 × 106 / kg body weight, each volume of 80ml ± 5ml, and the time interval between two transplants was 1 week; 2.2. Routine treatment group: only receiving routine treatment;
Interventions
BIOLOGICALTransplantation of self BMSCs
Bone marrow was collected, cultured in vitro and injected back into the body
Sponsors
Zhujiang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18-65 years old in the rehabilitation period of cerebral infarction (including subacute stage, chronic stage and sequelae stage, with onset time ≤ 3 years), regardless of gender; 2. Definite cerebral infarction in the blood supply area of middle cerebral artery confirmed by imaging; 3. There are clear neurological deficits, such as motor and cognitive dysfunction (National Institutes of Health Stroke Scale 7 \< NIHSS \< 21 points); 4. Those who agree to take effective contraceptive measures during the study period, and women of childbearing age have negative pregnancy test; 5. Sign the informed consent of the patient and agree to participate in all visits, examinations and treatments as required by the study protocol.
Exclusion criteria
1. Lacunar cerebral infarction; 2. Acute cerebral infarction, onset time \< 2 weeks; 3. Mild ischemic stroke or mild neurological impairment or severe ischemic stroke, with coma; 4. Patients with moyamoya disease, vascular malformation, hemangioma and carotid stenosis exceeding 70%; 5. Patients with severe heart valve disease or confirmed intractable atrial fibrillation; 6. Complicated with intracranial hemorrhage or tumor; 7. Patients with cerebral infarction caused by blood system diseases, or those with previous blood history or family history of blood diseases; 8. Any one of 5 items of hepatitis B virus (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody and syphilis spiral physical examination; 9. Those with severe respiratory or circulatory system or liver and kidney dysfunction who cannot tolerate treatment and examination; 10. Severe febrile disease or viral disease in the past 12 weeks; 11. Malignant tumor; 12. Those who have a previous history of autoimmune diseases or a family history of autoimmune diseases; 13. Previous history of drug allergy; 14. Pregnant or lactating women; 15. Those who are participating or have participated in this study or participated in other clinical trials within 12 weeks before enrollment; 16. Other circumstances that the investigator considers inappropriate for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The difference in National Institutes of Health Stroke Scale (NIHSS) score from baseline after the first transplant. | 96 weeks ±30 days after the first transplantation | The difference in National Institutes of Health Stroke Scale (NIHSS) score from baseline at week 96 ±30 days after the first transplant. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement rate of the modified Barthel Index Rating Scale score from baseline after the first transplant | 48 weeks ±15 days after the first transplantation | Improvement rate of the modified Barthel Index Rating Scale score from baseline at 48 weeks ±15 days after the first transplantation |
| Improvement rate of the modified Barthel Index Rating Scale score from baseline | 96 weeks ±30 days after the first transplantation | Improvement rate of the modified Barthel Index Rating Scale score from baseline at 96 weeks ±30 days after the first transplant |
| Improvement rate of Fugl-Meyer scale score from baseline after the first transplantation | 48 weeks ±15 days after the first transplantation | Improvement rate of Fugl-Meyer scale score from baseline at 48 weeks ±15 days after the first transplantation |
| Improvement rate of Simple Mental State Examination Scale (MMSE) score | 48 weeks ±15 days after the first transplantation | Improvement rate of Simple Mental State Examination Scale (MMSE) score from baseline at 48 weeks ±15 days after the first transplantation |
| The time course of the left abductor pollicis brevis and right abductor pollicis brevis of the motor evoked potential decreased from baseline after the first transplantation | 48 weeks ±15 days after the first transplantation | The time course of the left abductor pollicis brevis and right abductor pollicis brevis of the motor evoked potential decreased from baseline at 48 weeks ±15 days after the first transplantation |
| The difference from baseline in National Institutes of Health Stroke Scale (NIHSS) score after the first transplantation | 48 weeks ±15 days after the first transplantation | The difference from baseline in National Institutes of Health Stroke Scale (NIHSS) score at 48 weeks ±15 days after the first transplantation |
| The time course of the upper limb sensory evoked potential N9(left), N11(left), N20(left), N9(right), N11(right), N20(right) decreased from baseline after the first transplantation | 48 weeks ±15 days after the first transplantation | The time course of the upper limb sensory evoked potential N9(left), N11(left), N20(left), N9(right), N11(right), N20(right) decreased from baseline at 48 weeks ±15 days after the first transplantation |
| Rate of increase from baseline amplitude of the upper limb sensory evoked potential N9(left), N11(left), N20(left), N9(right), N11(right), N20(right) after the first transplantation | 48 weeks ±15 days after the first transplantation | Rate of increase from baseline amplitude of the upper limb sensory evoked potential N9(left), N11(left), N20(left), N9(right), N11(right), N20(right) at 48 weeks ±15 days after the first transplantation |
| Changes in CTA from baseline after the first transplantation | 48 weeks ±15 days after the first transplantation | Changes in CTA from baseline at 48 weeks ±15 days after the first transplantation |
| Changes in CTP from baseline after the first transplantation | 96 weeks ±30 days after the first transplantation | Changes in CTP from baseline at 96 weeks ±30 days after the first transplantation |
| Changes in mRS Scores from baseline after the first transplantation | 48 weeks ±15 days after the first transplantation | Changes in mRS Scores from baseline at 48 weeks ±15 days after the first transplantation |
| MT increase rate from baseline in the left abductor Pollicis brevis and right abductor pollicis brevis of the motor evoked potential after the first transplantation | 48 weeks ±15 days after the first transplantation | MT increase rate from baseline in the left abductor Pollicis brevis and right abductor pollicis brevis of the motor evoked potential at 48 weeks ±15 days after the first transplantation |
Countries
China
Contacts
Primary ContactJiang Xiaodan
Outcome results
None listed